Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hinoporon is a topical oral ointment developed by Showa Yakuhin Kako (now GC SHOWAYAKUHIN CORPORATION) for the treatment of periodontal diseases, including gingivitis and periodontitis, as well as stomatitis. It is a combination pharmaceutical product containing two primary active ingredients: hinokitiol and cetylpyridinium chloride. Hinokitiol is a natural monoterpenoid known for its potent broad-spectrum antibacterial, antifungal, and anti-inflammatory properties, which help reduce swelling and redness in the gums. Cetylpyridinium chloride is a quaternary ammonium antiseptic that further aids in reducing the bacterial load in the oral cavity by disrupting microbial cell membranes. The product is applied topically to the affected gingiva or oral mucosa, providing localized therapeutic effects to manage inflammation and infection associated with dental conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hinoporon.